FLGT
Fulgent Genetics, Inc.
Medical - Diagnostics & Research
Market Cap$444M
5Y Perf.-14.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FLGT vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1721.78T
5Y Perf.-58.6%
FLGT vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FLGT | DBVT |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Biotechnology |
| Market Cap | $444M | $1721.78T |
| Revenue (TTM) | $323M | $0.00 |
| Net Income (TTM) | $-61M | $-168M |
| Gross Margin | 40.6% | — |
| Operating Margin | -28.2% | — |
| Total Debt | $476K | $22M |
| Cash & Equiv. | $50M | $194M |
FLGT vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FLGT
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Fulgent Genetics, I… (FLGT) | 100 | 85.6 | -14.4% |
| DBV Technologies S.… (DBVT) | 100 | 41.4 | -58.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FLGT vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FLGT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
FLGT
Fulgent Genetics, Inc.
The Income Pick
FLGT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.97
- Rev growth 13.8%, EPS growth -39.7%, 3Y rev CAGR -19.5%
- 62.5% 10Y total return vs DBVT's -86.8%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Quality Compounder
DBVT is the clearest fit if your priority is quality and momentum.
- 0.3% margin vs FLGT's -18.8%
- +114.1% vs FLGT's -20.7%
Best for: quality and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FLGT | 13.8% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs FLGT's -18.8% |
| Stability / Safety | FLGT | Beta 0.97 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +114.1% vs FLGT's -20.7% |
| Efficiency (ROA) | FLGT | -5.0% ROA vs DBVT's -89.0% |
FLGT vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FLGT vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFLGTLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
FLGTFulgent Genetics, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
FLGT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FLGT5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
FLGT1/1
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
FLGT and DBVT operate at a comparable scale, with $323M and $0 in trailing revenue.
| Metric | FLGTFulgent Genetics,… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $323M | $0 |
| EBITDAEarnings before interest/tax | -$67M | -$112M |
| Net IncomeAfter-tax profit | -$61M | -$168M |
| Free Cash FlowCash after capex | -$124M | -$151M |
| Gross MarginGross profit ÷ Revenue | +40.6% | — |
| Operating MarginEBIT ÷ Revenue | -28.2% | — |
| Net MarginNet income ÷ Revenue | -18.8% | — |
| FCF MarginFCF ÷ Revenue | -38.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -3.0% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
FLGT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | FLGTFulgent Genetics,… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $444M | $1721.78T |
| Enterprise ValueMkt cap + debt − cash | $394M | $1721.78T |
| Trailing P/EPrice ÷ TTM EPS | -7.57x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.38x | — |
| Price / BookPrice ÷ Book value/share | 0.41x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
FLGT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
FLGT leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
FLGT delivers a -5.4% return on equity — every $100 of shareholder capital generates $-5 in annual profit, vs $-130 for DBVT. FLGT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x.
| Metric | FLGTFulgent Genetics,… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -5.4% | -130.2% |
| ROA (TTM)Return on assets | -5.0% | -89.0% |
| ROICReturn on invested capital | -6.4% | — |
| ROCEReturn on capital employed | -8.0% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.13x |
| Net DebtTotal debt minus cash | -$50M | -$172M |
| Cash & Equiv.Liquid assets | $50M | $194M |
| Total DebtShort + long-term debt | $476,000 | $22M |
| Interest CoverageEBIT ÷ Interest expense | -354.75x | -189.82x |
FLGT leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,344 today (with dividends reinvested), compared to $2,044 for FLGT. Over the past 12 months, DBVT leads with a +114.1% total return vs FLGT's -20.7%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.4% vs FLGT's -23.3% — a key indicator of consistent wealth creation.
| Metric | FLGTFulgent Genetics,… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -41.7% | +5.5% |
| 1-Year ReturnPast 12 months | -20.7% | +114.1% |
| 3-Year ReturnCumulative with dividends | -54.9% | +20.4% |
| 5-Year ReturnCumulative with dividends | -79.6% | -66.6% |
| 10-Year ReturnCumulative with dividends | +62.5% | -86.8% |
| CAGR (3Y)Annualised 3-year return | -23.3% | +6.4% |
DBVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — FLGT and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
FLGT is the less volatile stock with a 0.97 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.8% from its 52-week high vs FLGT's 48.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FLGTFulgent Genetics,… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.97x | 1.26x |
| 52-Week HighHighest price in past year | $31.04 | $26.18 |
| 52-Week LowLowest price in past year | $13.46 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +48.1% | +76.8% |
| RSI (14)Momentum oscillator 0–100 | 42.8 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 688K | 253K |
Evenly matched — FLGT and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
FLGT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates FLGT as "Buy" and DBVT as "Buy". Consensus price targets imply 141.3% upside for FLGT (target: $36) vs 130.5% for DBVT (target: $46).
| Metric | FLGTFulgent Genetics,… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $36.00 | $46.33 |
| # AnalystsCovering analysts | 9 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.5% | 0.0% |
FLGT leads this category, winning 1 of 1 comparable metric.
Key Takeaway
FLGT leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). DBVT leads in 2 (Income & Cash Flow, Total Returns). 1 tied.
Best OverallFulgent Genetics, Inc. (FLGT)Leads 3 of 6 categories
Loading custom metrics...
FLGT vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is FLGT or DBVT a better buy right now?
Analysts rate Fulgent Genetics, Inc.
(FLGT) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FLGT or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -66. 6%, compared to -79. 6% for Fulgent Genetics, Inc. (FLGT). Over 10 years, the gap is even starker: FLGT returned +62. 5% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FLGT or DBVT?
By beta (market sensitivity over 5 years), Fulgent Genetics, Inc.
(FLGT) is the lower-risk stock at 0. 97β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 29% more volatile than FLGT relative to the S&P 500. On balance sheet safety, Fulgent Genetics, Inc. (FLGT) carries a lower debt/equity ratio of 0% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — FLGT or DBVT?
On earnings-per-share growth, the picture is similar: Fulgent Genetics, Inc.
grew EPS -39. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — FLGT or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -18. 8% for Fulgent Genetics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -28. 2% for FLGT. At the gross margin level — before operating expenses — FLGT leads at 40. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — FLGT or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is FLGT or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Fulgent Genetics, Inc.
(FLGT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97)). Both have compounded well over 10 years (FLGT: +62. 5%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between FLGT and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.